chevron_leftBack
As of 14 June 2026, GlycoMimetics, Inc. has a market cap of $10.13M USD, ranking #41217 globally and #5326 in the United States.
It ranks #3665 in the Healthcare sector, and #715 in the Biotechnology industry.
Key Stats
Market Cap
$10.13MUSD
Enterprise Value
$5.1MUSD
EBITDA (TTM)
-$23.76MUSD
Net Income (TTM)
-$29.49MUSD
PB Ratio
3.2
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Biotechnology
CEO
Harout Semerjian
open_in_new
Employees
4
Founded
2003
IPO
10 Jan 2014
Website
glycomimetics.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -5.4% | -19% | -39% | -39% | -36% | -40% |
News
Loading...
GLYC Analyst Forecasts
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
GLYC
GlycoMimetics Inc
ISIN: US38000Q1022
Shares Out.:
Shares Outstanding:
64.532M1
Shares Float:
56.118M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
NQ:
NASDAQ:
BA:
Barron's:
MS:
Morningstar:
|
0.1570 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About GlycoMimetics, Inc.
GlycoMimetics, Inc. engages in the discovery and development of therapies for cancers and inflammatory diseases in the United States. The company was founded in 2003 and is based in Monrovia, Maryland.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NASDAQ: AMGN
|
$182.42B
2M%
|
23.9
|
|
NASDAQ: GILD
|
$159.92B
2M%
|
19.0
|
|
NASDAQ: NTRA
|
$27.6B
272K%
|
-
|
|
NYSE: IQV
|
$26.3B
259K%
|
20.0
|
|
NASDAQ: UTHR
|
$25.03B
247K%
|
20.4
|
|
NASDAQ: MRNA
|
$18.13B
179K%
|
-
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
EBR: ARGX
|
$47.84B
472K%
41.39B EUR
|
39.9
|
|
KRX: 207940
|
$44.84B
442K%
68.19T KRW
|
35.5
|
|
ASX: CSL
|
$42.36B
418K%
60.27B AUD
|
29.3
|
|
SIX: LONN
|
$42.3B
417K%
33.71B CHF
|
37.2
|
|
KRX: 068270
|
$28.11B
277K%
42.76T KRW
|
43.8
|
|
NASDAQ: BNTX
|
$25.69B
253K%
|
-
|
chevron_leftBack